A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion
Executive Summary
Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues
You may also be interested in...
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
When It Comes To Antibody Technology, Pfizer's On The Prowl
Pfizer's latest partnership in the space is with Theraclone Sciences, a Seattle start-up with an antibody technology that uses human B cells.